🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Phase 3 LEAP-015 Len/pembro + chemo vs chemo advanced G/GEJ adeno ➡️improvements PFS/ORR ➡️no imp in OS ; curves separate 15 mths ➡️60% grade 3/4 AEs, 24 deaths exp arm #ASCO25 ASCO OncoAlert

🔥Claudin 18.2 CAR-T(Satri-cel)vs physician choice G/GEJC ➡️ 2/3 lines tx ➡️mPFS 3.25 vs 1.8 HR 0.37 ➡️mOS 7.9 vs 5.5 HR 0.69 -when receiving tx 8.6 vs 5.5 mths HR 0.6 ➡️serious TRAEs 35%, 1 death each arm Exciting CAR-T in solid tumour with signals! @asco #ASCO25 OncoAlert

⭐️CASSANDRA phase 3 trial of PAXG vs mFFX in R/BR #PDAC ➡️ 3 yr EFS 31% vs 13%; OS immature ➡️phase2 initially then renamed phase3 ➡️somehow no diff in AEs! ➡️2 consecutive ⬆️ca19.9 =event ? Molecular diff in arms -exciting study- warrants further ix ASCO OncoAlert #ASCO25

PANOVA-03 LAPC GnP vs GnP + TTFields #ASCO25 ASCO OncoAlert ➡️571 patients randomised ➡️mOS 16.2 mths vs 14.2mths ➡️pain free survival longer ➡️mainly skin reactions for TTFields

GnP vs GnP+elraglusib in advanced #PDAC ➡️2:1 randomisation ➡️interesting inhibitor of GSK-3beta ➡️mOS 10.1 vs 7.2 mths GNP arm did poorly and still mOS <1 yr #ASCO25 @asco OncoAlert

🔥POLCAGB Ph 3 neoadjuvant chemo vs neoadjuvant chemorads + chemo in locally adv GBC ➡️ closed at interim due to poor accrual 124 pts randomised ➡️ORR 74% vs 36% ➡️mOS 22mths vs 10ths Imp data - rads has a role! Nb 20% her2 amp in GBC- needs explored #ASCO25 ASCO OncoAlert

TEDOPAM - maintenance randomised phase 2 vaccine trial #PDAC Induction mFFX- Folfiri vs Folfiri+ OSE2101 (TAAs) ➡️106 pts ➡️met primary endpoint of 12mth OS>50%; ➡️But control arm mOS 17 vs vaccine arm 15mths ➡️highlights benefit maintenance approaches ASCO OncoAlert #ASCO25

🔥NeoPancOne🇨🇦 ➡️mFFX in resectable PDAC ➡️exploring GATA6&subtypes ➡️mEFS &OS 16.3 &34.2mths ➡️1yr EFS 90% in GATA6 hi vs 50% lo ➡️1yr OS classical 95% vs.57% basal-like ⭐️Time to subtype upfront in all PDAC recognising plasticity OncoAlert #ASCO25 Ontario Institute for Cancer Research (OICR) Princess Margaret Cancer Centre

Professional presentation by Ronan Andrew McLaughlin also highlighting N.B. Adequate tissue for analysis: 98% research biopsies enabled success Pancreatic Cancer UK

Dear Colleagues Thank you for Another amazing day at our Annual #OncoAlert5k 🏃‍♀️at #ASCO25 , we look forward to seeing you all soon for another great day of camaraderie Safe Travels Home🏡 Gil Morgan, MD & OncoAlert #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD, PhD

Optimal approach in BR-PDAC/LAPC ✅starting with neoadjuvant therapy ❓is there a role for switch tx ?PAXG? ❓how do we incorporate CA19.9 dynamics ❓ what’s the best biomarker Fantastic talk from Bas Groot Koerkamp #PDAC #EAHPBA2025

Breaking news! Pump vs transplant is no longer a debate❤️. The parties (dr. Kingham and dr. Chapman) have come to agreement - transplant perfectly fits where #HAIP chemo fails. Ville Sallinen Grainne O'Kane can be congratulated as peacemakers #eahpba2025 Kristoffer Lassen Pål-Dag Line

“Transplant oncology is chasing the highest tumor load associated with cure” Great update from Vincenzo Mazzaferro, including new data on immune responses in the transplanted liver🤩 #eahpba2025 #transplantoncology

🔥Hot Topic in Liver Transplantation Journal (LTxJournal)! An international consensus conference was convened by the ILTS and the ILCA to establish a more universal consensus regarding #livertransplantation for oncologic indications. 👀 Read the Consensus statement: bit.ly/4kVBYmV

Tomorrow! the role of immunotherapy in the neoadjuvant setting is growing++ ✅#SITC summit on future of clinical trial design #endpoints ✅advances, opportunities & challenges 🔥Promises to be a superb &engaging summit Society for Immunotherapy of Cancer Patrick Forde 👇 Trinity St James's Cancer Institute UCD Cancer Trials

Congrats to oncology trainee Mary O’Reilly presenting data from her PhD on early onset colorectal cancer at ESMO GI 2025 ESMO - Eur. Oncology Ray McDermott Grainne O'Kane St Vincent's University Hospital (SVUH)

#TumorBoardTuesday 😮We had a rare #ASCO25 with several key🗝️updates in #PancreaticCancer So to put this in context: 📢Join us Tuesday, 07-08-25 at 8PM ET as Dr. Shubham Pant & Daniel Haldar 🗣️Optimizing 1L Treatment Selection in mPDAC RT and bring others into the discussion‼️